NT-112
KRAS G12D
AstraZenecaPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the KRAS G12D cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eli-002 7P Elicio Therapeutics | Phase 1/2 | CCC |
Irinotecan TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1/2 | CCC |
FLUOROURACILUM TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1/2 | CCC |
Calcium folinate pentahydrate TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1/2 | CCC |
Cetuximab TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1/2 | CCC |
View all 21 →
Same molecule, other indications
NT-112 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →